Treatment of Opioid Use Disorder - East Lansing, MI - Friday, September 17, 2021

Product not yet rated

  • Registration Closed
Treatment of Opioid Use Disorder Blended Course

Host: Michigan State Medical Society
Friday, September 17, 2021 | 1:00 pm - 5:30 pm ET
Online Portion Due: Thursday, September 16, 2021
Blended Course

Overview

This 8-hour, blended course (4-hour on-demand, 4-hour live) provides required education to qualify for the waiver to prescribe buprenorphine in an office-based setting and covers essential information for providers to identify, assess, diagnose, and manage patients with opioid use disorder (OUD).  

This blended course combines 4 hours of online learning followed by 4 hours of live learning. The live portion of the course builds off content delivered in the online portion. Course faculty are expecting learners to complete the online portion before attending the live portion. You must complete both portions to receive credit for the course. ASAM is an approved provider by CSAT/SAMHSA of DATA 2000 training.

The target audience for this introductory course includes: 

  • Physicians who wish to obtain a waiver to prescribe buprenorphine in office-based treatment of opioid use disorders.
  • Clinicians and healthcare team members working with providers who prescribe buprenorphine in office-based treatment of opioid use disorders.

This course addresses the following ACGME Competencies: Patient Care and Medical Knowledge.

Learning Objectives

Module 1 

  1. Assess patients for the full spectrum of harmful opioid use including misuse and use disorders
  2. Describe the current epidemiologic trends in opioid misuse including overdose and use disorders
  3. Recall opioid use neurobiology as it applies to the development of an opioid use disorder and relapse risk
  4. Summarize the laws regulating office-based opioid treatment including the Drug Addiction Treatment Act of 2000 and the Comprehensive Addiction and Recovery Act of 2016
  5. Summarize the clinical pharmacology, efficacy and safety of methadone, buprenorphine and naltrexone in treating opioid use disorders

Module 2

  1. Identify and assess patients who are appropriate for treatment with medications for an opioid use disorder in an office-based setting
  2. Describe procedures for setting up office systems to support medication prescribing for opioid use disorders
  3. Describe procedures for initiating, stabilizing, maintaining, monitoring and modifying treatment of patients on buprenorphine or naltrexone

Module 3

  1. Summarize the assessment and management of patients with psychiatric and medical co-morbidities associated with opioid use disorders
  2. Describe unique issues of treating adolescents, young adults, pregnant and postpartum patients maintained on medications for opioid use disorders
  3. Summarize acute and chronic pain management strategies for patients with an opioid use disorder

Overall

Apply for a waiver to prescribe buprenorphine to patients with opioid use disorder

Fees

Rate DescriptionRate
ASAM Member$0
Non-Member$0
Retired Member$0
Associate Member$0
Resident Member*$0
Student Member*$0

(*) Residents, Fellows-in-training, Interns, and Students must join ASAM to receive a discounted registration rate. 

  • Click here to become an ASAM member.
  • Residents, Fellows-in-training, and Interns: National and Chapter membership dues apply.
  • There is no charge for Students to become a Member, but verification of student status is required. 
  • Membership Question?  Call ASAM at 1.301.656.3920, email us, or view the ASAM website for more information.

Refunds & Cancellations

All ASAM e-Learning Center refund requests must be made in writing to education@asam.org within 90 days of purchase. Those requesting refunds for courses that are in progress will receive partial refunds or e-Learning Center credit. Automatic full refunds will be made for any course with a live-course component that has been cancelled.

Registration Deadline: 09/17/2021

Instructions

  1. Click the Contents tab and select Complete Course Overview.  After viewing the entire module, continue to complete the remaining modules and return to the Contents tab.
  2. Click Complete Evaluation - On-Demand to answer evaluation questions. Scroll down on all questions, there are answers that expand past the size of the window. Submit the evaluation (the next box should activate, and the evaluation box should turn green with a white check mark).
  3. Click the Contents tab and select Attend Live Virtual Course.  After attending the live course, return to the Contents tab.
  4. Click Complete Evaluation - Live to answer evaluation questions. Scroll down on all questions, there are answers that expand past the size of the window. Submit the evaluation (the next box should activate, and the evaluation box should turn green with a white check mark).
  5. Click the button Claim Credits in the box titled Claim Certificate of Completion. Choose the type of credit and click submit. Click the button View/Print Certificate to save or print your certificate. If you ever lose your certificate, you can come back to the ASAM e-Learning Center and view it on your transcript (found in the Dashboard).

Need Assistance?

If you have are experiencing any log in issues, cannot access a course, need assistance claiming credit, or have other questions or concerns, please e-mail Education@asam.org for assistance.

For learners who may have difficulty typing, moving a mouse or reading, Essential Accessibility is an application available for use to assist.

David Galbis-Reig, MD, DFASAM

MD, DFASAM

David Galbis-Reig MD, FASAM received his Doctor of Medicine degree from Virginia Commonwealth University in Richmond, Virginia in 1999. He completed a residency in Internal Medicine at Aurora Sinai Medical Center in Milwaukee, Wisconsin in 2004. He is board certified in Internal Medicine by the American Board of Internal Medicine and Addiction Medicine by the American Board of Addiction Medicine. He has been the Director of Medical Services on the Inpatient Mental Health and Addiction Unit at Wheaton Franciscan Healthcare – All Saints since 2005 in which capacity he has passionately advocated for appropriate medical treatment of patients with mental health and addictive diseases. Dr. Galbis-Reig is currently also involved in numerous educational activities to decrease prescription drug abuse and decrease the burden of addiction to opioids in Racine and Kenosha Counties. He is an active member of the American Society of Addiction Medicine (ASAM), the current secretary of the Wisconsin Society of Addiction Medicine (WiSAM), and a contributing author to the recently published ASAM white paper on the science of drug testing. He is a member of the Wisconsin Marijuana Prevention Ad-Hoc Committee of the State Council on Alcohol and Other Drug Abuse (SCAODA). He is also an active member of the Wisconsin Medical Society and a member of the Board of Directors of the Wisconsin Medical Society Foundation.

Disclosures- Hospira- Ownership, Abbott Pharmaceuticals- Ownership, Abbive- Ownership 


CME, CE, CEU and Other Credit Types

ACCME Accredited with Commendation

ACCME Accreditation Statement
The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA Credit Designation Statement
The American Society of Addiction Medicine designates this enduring activity for a maximum of 4 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The American Society of Addiction Medicine designates this live activity for a maximum of 4 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NAADAC, the Association for Addiction Professionals
This activity has been approved by the American Society of Addiction Medicine, as a NAADAC Approved Education Provider, for educational credits. NAADAC Provider #295, ASAM is responsible for all aspects of the programming.

California Association for Drug/Alcohol Educators (CAADE)
This educational program is approved by CAADE: #CP40 999 1222

California Association of DUI Treatment Centers (CADTP)
This educational program is approved by CADTP: #205

California Consortium of Addiction Programs and Professionals (CCAPP)
This educational program is approved by CCAPP: #OS-20-330-1222

Continuing Education Credits (CEUs)
Non-physician participants will receive a certificate of attendance upon completion of the activity and an online evaluation confirming their participation. Participants should submit his/her certificate of attendance to their professional organization/institute.

Maintenance of Certification (MOC) or Continuing Certification Programs (CCP)

American Board of Medical Specialties (ABMS)
Through the American Board of Medical Specialties (“ABMS”) ongoing commitment to increase access to practice relevant Continuing Certification Activities through the ABMS Continuing Certification Directory, The ASAM Treatment of Opioid Use Disorder Course: Includes Waiver Qualifying Requirements has met the requirements as a MOC Part II CME Activity (apply toward general CME requirement) for the following ABMS Member Boards: Anesthesiology, Family Medicine, Physical Medicine and Rehabilitation, Preventive Medicine, Psychiatry and Neurology, Radiology

American Board of Preventive Medicine (ABPM)
The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 8 LLSA credits towards ABPM MOC Part II requirements.

American Board of Anesthesiology (ABA)
This activity contributes to the CME component of the American Board of Anesthesiology’s redesigned Maintenance of Certification in Anesthesiology TM (MOCA®) program, known as MOCA 2.0®.

American Board of Pediatrics (ABP)
Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participant and feedback to the participant, enables the participant to earn a maximum of 8 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.

American Board of Internal Medicine (ABIM)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credits.

American Board of Surgery (ABS)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME and/or Self-Assessment requirements of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit

American Board of Psychiatry and Neurology (ABPN)
Successful completion of this CME activity can be used to satisfy the American Board of Psychiatry and Neurology’s (ABPN) CME requirement for Maintenance of Certification program.

American Board of Addiction Medicine (ABAM)
Successful completion of this activity can be used to satisfy the American Board of Addiction Medicine (ABAM) for Tmoc as credits towards ABAM LLSA Part II requirements.

Disclosure Information

In accordance with disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all CME activities. These policies include resolving all possible conflicts of interest for the Planning Committees, CME Committee, MEC, and Faculty. All activity Planning Committee members and Faculty have disclosed relevant financial relationship information. The ASAM CME Committee has reviewed these disclosures and determined that the relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

Key:

Complete
Failed
Available
Locked
Complete Pre-Course Survey
2 Questions
2 Questions Please answer the following
Complete Course Overview
Begin self-paced component package.
Begin self-paced component package. This activity will take 1 hour to complete. This activity was last reviewed and updated in February 2021.
Complete Module 1 - Identifying, Assessing, and Diagnosing Patients with Opioid Use Disorder
Begin self-paced component package.
Begin self-paced component package. This activity will take 1 hour to complete. This activity was last reviewed and updated in February 2021.
Complete Module 2 - Determining Treatment Plan for Patients with Opioid Use Disorder
Begin self-paced component package.
Begin self-paced component package. This activity will take 1 hour to complete. This activity was last reviewed and updated in February 2021.
Complete Module - Harm Reduction and Stigma
Begin self-paced component package.
Begin self-paced component package. This activity will take 1 hour to complete. This activity was last reviewed and updated in February 2021.
Complete Evaluation - On-Demand
16 Questions
16 Questions Scroll down on evaluation, there may be questions that expand past the size of the window.
Attend Live Virtual Course
09/17/2021 at 1:00 PM (EDT)   |  270 minutes
09/17/2021 at 1:00 PM (EDT)   |  270 minutes Learners may join 15 minutes prior to start time. Audio is via computer speakers/headphones. There is no option to join via telephone.
Complete Evaluation - Live
16 Questions
16 Questions Scroll down on evaluation, there may be questions that expand past the size of the window.
Claim Credits & Certificate
Up to 8.00 medical credits available  |  Certificate available
Up to 8.00 medical credits available  |  Certificate available Participants should claim only the credits commensurate with the extent of their participation in the activity.

How to Apply for a Waiver

Physicians

SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.

Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.

If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.

Other Approved Prescribers

Apply

NPs and PAs may upload copies of their training certificates on the Waiver Notification Form. NPs and PAs who have completed the 24 hours of required training may seek to obtain a DATA 2000 waiver for up to 30 patients by completing the Waiver Notification Form. Effective February 27, 2017, SAMHSA will only accept electronic submissions of the NOI.

These waiver applications are forwarded to the Drug Enforcement Administration (DEA), which will assign the NP or PA a special identification number. DEA regulations require this number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with the NP’s or PA’s regular DEA registration number.

SAMHSA shall review waiver applications within 45 days of receipt. If approved, NPs and PAs will receive a letter via email that confirms their waiver and includes their prescribing identification number. 

Qualify

To qualify for a waiver to treat patients with Opioid Use Disorder, NPs and PAs must:

  • Be licensed under state law to prescribe schedule III, IV, or V medications for pain
  • Complete no less than 24 hours of appropriate education through a qualified provider
  • Through other training or experience, demonstrate the ability to treat and manage OUD
  • If required by state law, supervision or working in collaboration with a qualifying physician to prescribe medications for the treatment of OUD may be required.

Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat OUD before you apply for the waiver.  Some states may have overriding state legislation that will prevent NPs from prescribing these medications even if Federal law allows it.

Overview of Legislation

Physicians

The Drug Abuse Treatment Act of 2000 (DATA 2000) specifies training is necessary for physicians to obtain a waiver to engage in office‐based treatment of opioid use disorders using drugs approved by the FDA on Schedules III, IV, and V. This course addresses those requirements using a curriculum approved by CSAT/SAMHSA and ASAM, who is one of the national organizations named in the DATA 2000 legislation as eligible to prepare and administer these courses.

Nurse Practitioners & Physician Assistants

On July 22, 2016, President Obama signed the Comprehensive Addiction and Recovery Act (CARA) into law. CARA authorizes qualified NPs and PAs to become waivered to prescribe buprenorphine in office-based settings for patients with Opioid Use Disorder (OUD) for a five-year period expiring in October 2021.    

To qualify, NPs and PAs must: 

  • Be licensed under state law to prescribe schedule III, IV, or V medications for pain  
  • Complete not less than 24 hours of appropriate education through a qualified provider
  • Through other training or experience, demonstrate the ability to treat and manage OUD  
  • If required by state law, be supervised or work in collaboration with a qualifying physician to prescribe medications for the treatment of OUD

HHS' announcement on November 16, 2016, enables NPs and PAs to immediately begin taking the 24 hours of required training. For the full HHS announcement, click here.

NPs and PAs can begin the training immediately by taking the 8-hour buprenorphine course ASAM currently offers or that other stakeholders offer (see below for more information). The remaining 16 hours will have to be completed with one training provider. ASAM is developing multiple 16-hour training course options and formats, including collaborations with:

The ASAM Treatment of Opioid Use Disorder Course has been made available in part by an unrestricted educational grant from Indivior Inc.